Arctoris was featured in Labiotech, in an article highlighting a collaboration between the Oxford-based automation company and Swiss software firm Molecule. The partnership aims to improve drug discovery by combining laboratory automation with digital tools designed to simplify the sharing and development of drug intellectual property.
The collaboration addresses a key challenge facing the pharmaceutical industry: the rising cost of drug development and declining returns on investment. Improving data quality, reproducibility, and collaboration across organizations is increasingly important as researchers work to accelerate the discovery of new medicines.
Through the partnership, Arctoris contributes its automated laboratory infrastructure, which enables high-precision experimentation and scalable data generation. Molecule brings an open-source software platform that helps researchers collaborate on drug discovery projects and attract investment while reducing legal and financial barriers associated with sharing intellectual property.
The article also highlights the broader trend toward automation in life sciences research. Technologies such as robotics, advanced analytics, and artificial intelligence are helping to improve the reliability of experimental data and enable more efficient drug discovery workflows.
By integrating automated experimentation with collaborative digital platforms, initiatives like the Arctoris–Molecule partnership aim to support a more transparent and efficient model for discovering and developing new therapies.
